SCHEMBL29625908

SCHEMBL29625908

Cc1cc(NC(N)=O)ccc1Oc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK39 Q9UEW8 1/20 0.58
DHODH Q02127 1/20 0.54
PGR P06401 1/20 0.53
AR P10275 1/20 0.53
NR1H4 Q96RI1 1/20 0.47
MAPT P10636 2/20 0.47
HSD17B10 Q99714 1/20 0.47
PNLIP P16233 3/20 0.46
GAA P10253 2/20 0.46
GFER P55789 1/20 0.46
C5AR1 P21730 1/20 0.46
PARG Q86W56 1/20 0.46
LTA4H P09960 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 2/20 0.45
NPC1 O15118 2/20 0.45
HTT P42858 1/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28479390 1.00 STK39 (0.58) STK39DHODHPGRARNR1H4
SCHEMBL21295412 0.89 STK39 (0.62) STK39DHODHPGRARNR1H4
SCHEMBL30744028 0.88 STK39 (0.60) STK39DHODHPGRARNR1H4
SCHEMBL21305446 0.88 STK39 (0.60) STK39DHODHPGRARNR1H4
SCHEMBL21295431 0.85 STK39 (0.58) STK39DHODHPGRARMAPT
SCHEMBL21305385 0.84 POLB (0.61) STK39DHODHPGRARMAPT
SCHEMBL30743998 0.84 STK39 (0.57) STK39DHODHPGRARNR1H4
SCHEMBL21295557 0.84 STK39 (0.57) STK39DHODHPGRARNR1H4
SCHEMBL21295331 0.83 STK39 (0.56) STK39DHODHPGRARMAPT
SCHEMBL23051396 0.81 KMT2A (0.58) STK39DHODHPGRARMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111819172-B Triazine derivatives for the treatment of neurotrophin related diseases 阿泽克制药公司 2024-02-06 CN disclosed
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS AlzeCure Pharma AB (SE) 2022-09-29 US disclosed
CN-114423743-A Triazine derivatives for the treatment of diseases associated with neurotrophic factors 阿泽克制药公司 2022-04-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306589-A1 TRIAZINE DERIVATIVES FOR TREATING DISEASES RELATING TO NEUROTROPHINS NTRK2, BDNF, NGF STK39 3105/4885DHODH 4691/4885PGR 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.